Market News Latest

West Syndrome Market to Observe Impressive Growth by 2030 | Key Companies – GW Pharmaceuticals, BioPharm Solutions, and Others

 Breaking News
  • No posts were found

West Syndrome Market to Observe Impressive Growth by 2030 | Key Companies – GW Pharmaceuticals, BioPharm Solutions, and Others

October 29
05:26 2021
West Syndrome Market to Observe Impressive Growth by 2030 | Key Companies - GW Pharmaceuticals, BioPharm Solutions, and Others
Delveinsight Business Research LLP
DelveInsight’s “West Syndrome Market Insights, Epidemiology, and Market Forecast 2030” report delivers an in-depth understanding of the historical and forecasted epidemiology as well as the West Syndrome Market Size and Share in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

The West Syndrome market report covers emerging drugs, current treatment practices, market share of the individual therapies, current and forecasted market size from 2017 to 2030. It evaluates the current treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market. 

West Syndrome Market

West Syndrome: An Overview

West syndrome is an age-related specific epileptic encephalopathy due to multiple and diverse causes. It is characterized by a unique type of seizure called epileptic (infantile) spasms and gross EEG abnormalities of hypsarrhythmia. Usually, West syndrome consists of a characteristic triad: infantile spasms, the arrest of psychomotor development, and hypsarrhythmia, although one element may be missing.

West Syndrome Market Key Facts

  • The National Organization for Rare Disorders (NORD) estimates that West syndrome affects 0.31/1000 live births in the United States, accounting for approximately 30% of all cases of epilepsy affecting infants.

  • The total diagnosed West Syndrome prevalent population in the 7 major markets was 8,601 in 2020.

  • As per DelveInsight, West Syndrome is more prevalent among males than in females.

  • The diagnosed prevalent cases of West Syndrome patients in the United States was 4,265 in 2020.

  • In the EU5 countries, the diagnosed prevalence of West Syndrome was observed to be maximum in France with 784 cases, followed by the United Kingdom with 738 cases in 2020. While, the least number of cases were found in Spain, with 475 cases in 2020.

  • In Japan, the diagnosed prevalence of West Syndrome was 1,166 in 2020.

Get FREE sample copy at: West Syndrome Therapeutics Market

Key Benefits of West Syndrome Market Report

  • The report provides an in-depth analysis of West Syndrome Market Size and Share till 2030 in the seven major markets.

  • The report will help in developing business strategies by understanding the West Syndrome Market Trends, key players, and ongoing developments that shape and drive the market growth in the upcoming years.

  • It covers West Syndrome current treatment practices, emerging drugs, market share of the individual therapies in the 7MM.

  • The report provides a detailed assessment of the West Syndrome market in terms of market drivers & barriers, unmet needs, market opportunities, patient population, detailed comparative analysis of pipeline products including clinical and non-clinical stage products, and other factors. 

West Syndrome Market 

The West Syndrome market size in the 7MM was estimated to be USD 182.4 Million in 2020. The West Syndrome market in the 7MM is expected to increase at a CAGR of 4.81% during the study period, i.e., 2018–2030. The key driver for the surge in market size is the rise in the number of prevalent cases

The market outlook section of the report helps to build a detailed comprehension of the historic, current, and forecasted West Syndrome market size and share by analyzing the impact of current therapies on the market, unmet needs, drivers, and barriers, and demand for better technology. 

The report gives a thorough detail of the West Syndrome market trend for each marketed drug and late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders.

West Syndrome Market Drivers

  • Clinical Development Activities

  • Product Innovations and Technological Advancements

  • Growing Number of Births and Rising Prevalence of Infantile Spasms

  • Support from Various Organizations

West Syndrome Epidemiology

The total diagnosed prevalent population of West Syndrome in the 7MM is expected to increase at a CAGR of 2.16% during the study period, i.e., 2018–2030.

The epidemiology section covers insights about the historical and current West Syndrome patient pool and forecasted trends for every seven major countries from 2017 to 2030. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides the diagnosed patient pool and their trends along with assumptions undertaken.  

West Syndrome Epidemiology Segmentation

  • Total Prevalent Population of West Syndrome

  • Total Diagnosed Prevalent Population of West Syndrome

  • Gender-specific Diagnosed Prevalent Population of West Syndrome

West Syndrome Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the West Syndrome market or expected to get launched in the market during the study period. The analysis covers West Syndrome market uptake by drugs; patient uptake by therapies; and sales of each drug. 

Report’s Drugs Uptake section helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allow the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

The report also covers the West Syndrome Pipeline Development Activities and provides valuable insights about different therapeutic candidates in Phase II, and Phase III stages and the key companies in the market involved in developing targeted therapeutics. It also analyses the recent Development such as collaborations, acquisitions, and mergers, licensing patent details, and other information for emerging therapies.

West Syndrome Therapeutics Analysis

The dynamics of the West Syndrome market is anticipated to change in the coming years owing to the improvement in the research and development activities in the therapeutics segment. The launch of emerging therapies is expected during the forecast period of 2021-2030.

Key Companies in the West Syndrome Market includes:

  • GW Pharmaceuticals

  • BioPharm Solutions

And several others.

West Syndrome Therapies covered in the report includes:

  • Epidiolex (GWP42003-P)

  • JBPOS0101

And many others.

Request for Sample @ West Syndrome Emerging Therapies and Key Companies

Table of Content

1. Key Insights

2. Executive Summary 

3. West Syndrome Competitive Intelligence Analysis

4. West Syndrome Market Overview at a Glance

5. West Syndrome Disease Background and Overview

6. West Syndrome Patient Journey

7. West Syndrome Epidemiology and Patient Population

8. West Syndrome Treatment Algorithm, Current Treatment, and Medical Practices

9. West Syndrome Unmet Needs

10. Key Endpoints of West Syndrome Treatment

11. West Syndrome Marketed Products

12. West Syndrome Emerging Therapies

13. West Syndrome Seven Major Market Analysis

14. Attribute Analysis

15. West Syndrome Market Outlook (7 major markets)

16. West Syndrome Access and Reimbursement Overview

17. KOL Views on the West Syndrome Market.

18. West Syndrome Market Drivers

19. West Syndrome Market Barriers

20. Appendix

21. DelveInsight Capabilities

22. Disclaimer

*The table of contents is not exhaustive; the final content may vary. 

Get FREE sample copy at:

About DelveInsight

DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end-to-end comprehensive solutions to improve their performance.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States